Novartis dealt another setback to broader Menveo use

Novartis ($NVS) hit another snag in its quest to broaden use of the meningococcal vaccine Menveo. The FDA has asked for more information on Menveo use in infants, delaying the company's ability to market the shot for that group. The setback could hobble Menveo as it seeks to compete with Sanofi's ($SNY) Menactra, an analyst told Dow Jones. Report

Suggested Articles

Humanigen has tapped Thermo Fisher to help scale production of monoclonal antibody lenzilumab for a possible emergency approval to treat COVID-19.

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform.